Inventory Quality vs. Audience Quality in Pharma Media
A two-axis diagnostic that keeps inventory quality and audience quality separate, so one strong dimension does not hide a weak one in pharma media.
The short answer
When pharma campaign results are weak, teams often blame either the inventory ("the sites are low quality") or the audience ("the data is wrong"). Both can be true at once, and a strong result on one can hide a problem with the other. A two-axis diagnostic keeps them separate.
Two different questions
Inventory quality asks: were the ads served in environments where they could be seen by real people in suitable context? Measures include viewability, invalid traffic, brand safety, and context.
Audience quality asks: were the ads served to the intended people? Measures include target-list reach, audience accuracy, and match method.
The two-axis grid
| High audience quality | Low audience quality | |
|---|---|---|
| High inventory quality | Right people, good environments. Performance problems are likely creative, frequency, or landing experience. | Good environments, wrong people. Common with contextual-only buys or broad segments. |
| Low inventory quality | Right people, poor environments. Common when cheap supply is used to reach a narrow list. | Neither is working. Fix both before testing anything else. |
Placing each partner or line item on this grid points to the right fix.
Measuring each axis
Inventory quality
- Viewability rate by the MRC standard
- Invalid traffic rate
- Share of impressions on made-for-advertising or low-quality domains
- Context suitability
- Supply path authorization, see ads.txt and sellers.json
Audience quality
- Reach against the intended universe
- Share of deterministic matches
- Validation against a truth set where available
- For DTC, see audience due diligence
How one hides the other
A partner with excellent viewability may be serving viewable ads to the wrong people. A partner with precise NPI targeting may be buying cheap app inventory where prescribers rarely engage. Averages across partners hide these patterns. Look at each partner separately.
Trade-offs
Improving one axis can affect the other. Tightening inventory quality can reduce available supply and lower reach against a narrow list. Tightening audience quality can push delivery to cheaper inventory. Monitor both when making changes. See video quality scorecard for video-specific measures.
Practical takeaway
Plot every partner on the two-axis grid using your latest data. For each, write the one fix most likely to move it toward the top-left quadrant.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.